EXAS
Exact Sciences Corp
$
45.090
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
45.8485
Open
45.430
VWAP
45.40
Vol
2.85M
Mkt Cap
8.54B
Low
44.800
Amount
129.45M
EV/EBITDA(TTM)
150.59
Total Shares
184.53M
EV
10.02B
EV/OCF(TTM)
32.78
P/S(TTM)
2.86
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
807.68M
+14.27%
0.076
-121.19%
826.64M
+15.87%
0.186
-410.57%
809.13M
+14.18%
0.159
-224.25%
Estimates Revision
The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 1.63% over the past three months. During the same period, the stock price has changed by -20.81%.
Revenue Estimates for FY2025
Revise Upward
+1.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+44.19%
In Past 3 Month
Stock Price
Go Down
-20.81%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast EXAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 66.44 USD with a low forecast of 53.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 45.090
Low
53.00
Averages
66.44
High
75.00
Current: 45.090
Low
53.00
Averages
66.44
High
75.00
BTIG
Mark Massaro
Buy
downgrade
$65 -> $60
2025-08-12
Reason
BTIG
Mark Massaro
Price Target
$65 -> $60
2025-08-12
downgrade
Buy
Reason
BTIG analyst Mark Massaro lowered the firm's price target on Exact Sciences (EXAS) to $60 from $65 and keeps a Buy rating on the shares. The firm's management team meetings after the "surprising" Freenome deal has left it more positive for the outlook of both companies, the analyst tells investors in a research note. Exact Sciences has pivoted very quickly from its setback in its own blood program and de-risked to some extent the threat of blood-based competition from Guardant Health (GH), the firm added.
Piper Sandler
Overweight
downgrade
$70 -> $60
2025-08-11
Reason
Piper Sandler
Price Target
$70 -> $60
2025-08-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Exact Sciences to $60 from $70 following quarterly results. The firm keeps an Overweight rating on the shares.
Barclays
Overweight
maintain
$65 -> $55
2025-08-07
Reason
Barclays
Price Target
$65 -> $55
2025-08-07
maintain
Overweight
Reason
Barclays lowered the firm's price target on Exact Sciences to $55 from $65 and keeps an Overweight rating on the shares following the earnings report. The firm says not a lot changed in blood-based screening market dynamics over the long term.
TD Cowen
Dan Brennan
Buy
downgrade
$75 -> $66
2025-08-07
Reason
TD Cowen
Dan Brennan
Price Target
$75 -> $66
2025-08-07
downgrade
Buy
Reason
TD Cowen analyst Dan Brennan lowered the firm's price target on Exact Sciences to $66 from $75 and keeps a Buy rating on the shares. The firm notes the stock traded off post close, this despite posting a strong Q2. The issue was the company's CRC blood data was a big disappointment. But the good news is, TD Cowen points out, Exact Sciences moved aggressively, signing a deal with competitor Freenome to get access to their blood-based CRC test and pipeline, with FDA approval expected in 2026. The firm says the selloff looks overdone.
Leerink
Outperform
maintain
$90
2025-06-27
Reason
Leerink
Price Target
$90
2025-06-27
maintain
Outperform
Reason
Leerink reiterated an Outperform rating and $90 price target on Exact Sciences after the U.S. Supreme Court upheld the U.S. Preventive Services Task Force coverage mandate, a positive for Exact Sciences. This mandate has required commercial insurance to cover Cologuard without cost sharing, the analyst tells investors in a research note. The firm believes the outcome was in question but still reachable, and that the stock should find relief on Friday, as this resolves one of the main negative risks to the company and its commercial execution.
Barclays
Overweight
downgrade
$75 -> $65
2025-06-24
Reason
Barclays
Price Target
$75 -> $65
2025-06-24
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Exact Sciences to $65 from $75 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Exact Sciences Corp (EXAS.O) is 64.08, compared to its 5-year average forward P/E of -64.50. For a more detailed relative valuation and DCF analysis to assess Exact Sciences Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-64.50
Current PE
64.08
Overvalued PE
55.92
Undervalued PE
-184.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
8.72
Current EV/EBITDA
18.58
Overvalued EV/EBITDA
89.01
Undervalued EV/EBITDA
-71.57
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
5.85
Current PS
2.58
Overvalued PS
8.95
Undervalued PS
2.74
Financials
Annual
Quarterly
FY2025Q2
YoY :
+15.99%
811.09M
Total Revenue
FY2025Q2
YoY :
-88.14%
-2.15M
Operating Profit
FY2025Q2
YoY :
-92.50%
-1.19M
Net Income after Tax
FY2025Q2
YoY :
-88.89%
-0.01
EPS - Diluted
FY2025Q2
YoY :
-34.44%
46.68M
Free Cash Flow
FY2025Q2
YoY :
-0.24%
69.35
Gross Profit Margin - %
FY2025Q2
YoY :
-818.64%
4.24
FCF Margin - %
FY2025Q2
YoY :
-93.36%
-0.15
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
233.0K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
130.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.0M
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 614.09% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
453.1K
Volume
2
6-9
Months
63.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
88.3K
Volume
Months
6-9
8
725.9K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
233.0K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
130.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.0M
USD
Months
EXAS News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
09:49:37
Exact Sciences expands colorectal cancer screening partnership with Humana
2025-07-10 (ET)
2025-07-10
15:25:10
Patent board invalidates Exact Sciences patent for stool samples
2025-07-09 (ET)
2025-07-09
06:03:34
Exact Sciences announces its Oncodetect MRD test receives Medicar coverage
Sign Up For More Events
Sign Up For More Events
News
5.0
08-15TipRanksCathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stake in Exact Sciences and Robinhood Stocks
4.0
08-12BenzingaMicron To Rally More Than 49%? Here Are 10 Top Analyst Forecasts For Tuesday
3.0
08-11BenzingaTop 3 Health Care Stocks That Are Preparing To Pump This Month
Sign Up For More News
People Also Watch
MLI
Mueller Industries Inc
92.070
USD
+0.55%
CUBE
CubeSmart
39.000
USD
-1.27%
EHC
Encompass Health Corp
120.220
USD
-0.13%
DBX
Dropbox Inc
27.900
USD
+0.29%
GLBE
Global-E Online Ltd
32.550
USD
+5.65%
BRBR
Bellring Brands Inc
38.490
USD
+0.34%
DRS
Leonardo DRS Inc
42.730
USD
+2.54%
LAD
Lithia Motors Inc
304.570
USD
+1.23%
WCC
Wesco International Inc
209.860
USD
+1.77%
FAQ
What is Exact Sciences Corp (EXAS) stock price today?
The current price of EXAS is 45.09 USD — it has decreased -1.12 % in the last trading day.
What is Exact Sciences Corp (EXAS)'s business?
What is the price predicton of EXAS Stock?
What is Exact Sciences Corp (EXAS)'s revenue for the last quarter?
What is Exact Sciences Corp (EXAS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Exact Sciences Corp (EXAS)'s fundamentals?
How many employees does Exact Sciences Corp (EXAS). have?